ClinicalTrials.gg
CompletedNCT01271777Updated Sep 24, 2012

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

A Phase 2 interventional study of GFT505 80mg and Placebo in Insulin Resistance and Abdominal Obesity, sponsored by Genfit. Completed at 2 sites in France. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-24.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Insulin Resistance with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Insulin Resistance · France.

Enrollment
39th of 52
22 · median 40
Started
2011
with 3 others
Phase 2
4 of 66
none open now
Registered
21st of 66
by date

Among the 66 studies in Insulin Resistance with a site in France, this one is the 39th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2011, is one of 4 in phase 2, and was the 21st registered.

Insulin Resistance

2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

10 of the 66 studies in Insulin Resistance with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Insulin Resistance with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.

Read the detailed description

The study period per patient is 26 weeks: a selection period will precede a 8-week treatment period, a 6-week wash out period, a second 8-week treatment period in the second arm of treatment and a 2- week follow-up period.

Schedule:

  • Selection visit prior to treatment period (D-14 and D-1)
  • D0 : randomisation visit
  • Period T1: first period of treatment with GFT505 80mg or placebo for 8 weeks (D1 to D56)
  • Wash out period for 6 weeks (D57 to D98)
  • Period T2: second period of treatment with GFT505 80mg or placebo for 8 weeks (D99 to D154)
  • Follow up period for 2 weeks (D155 to D169)
03

Conditions studied

  • Insulin Resistance
  • Abdominal Obesity

Keywords

  • Pre-diabetes
  • Clamp technique
  • PPARs
  • Insulin resistance
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Waist circumference ≥94cm.
  • ≤ 45kg/m2.
  • Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) > 3.

Exclusion criteria

Exclusion Criteria:

  • Blood Pressure > 160 / 95 mmHg.
  • Diabetes mellitus 1 or 2.
  • Historical of bariatric surgery.
  • Patient treated with a lipid-decreasing medication.
  • A fasting plasma triglycerides concentration > 400mg/dL or a plasma Low Density Lipoprotein Cholesterol (LDL-c)concentration > 220mg/dL.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GFT505 80mg

    Drug: GFT505 80mg

  • Placebo comparator
    Matching placebo

    Drug: Placebo

Interventions

  • hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast

  • DrugPlacebo

    hard gelatin capsules, oral administration, 4 capsules per day before breakfast

06

What researchers measure

Primary outcomes

  1. Glucose Infusion Rate (GIR)

    To evaluate in each patient the differences in Glucose Infusion Rate (GIR) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.

    Time frame: 8 weeks

Secondary outcomes

  1. Differences in Hepatic Glucose Production (HGP) in each patient

    To evaluate in each patient the differences in Hepatic Glucose Production (HGP) measured at the end of 8 weeks treatment periods with GFT505 (80 mg/day per os) or placebo according to a cross-over design.

    Time frame: 8 weeks

  2. Changes in GIR (Glucose Infusion Rate)

    To compare the changes from baseline to endpoint in Glucose Infusion Rate (GIR). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.

    Time frame: 8 weeks

  3. Changes in HGP (Hepatic Glucose Production)

    To compare the changes from baseline to endpoint in Hepatic Glucose Production (HGP). The baseline will be defined as the values of glucose clamp at V2. The same baseline will be used for the 2 periods. End-points will be defined as glucose clamp values at V4 for the first period and as glucose clamp values at V7 for the second period.

    Time frame: 8 weeks

07

Study locations

2 sites
  • Site n°1
    Nantes Cedex 1, 44093, France
  • Site n°2
    Pierre Bénite, 69310, France
08

References and documents

Publications

  • Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013 Oct;36(10):2923-30. doi: 10.2337/dc12-2012. Epub 2013 May 28. PubMed 23715754 ↗
  • Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29. PubMed 23703580 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2011
First posted
Jan 7, 2011
Start
Jan 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
Sep 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01271777
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Jan 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Sep 24, 2012

Study contacts

Rémy Hanf, Development Director
study director · Genfit, France
Bertrand CARIOU, Pr.
study chair · University Hospital of Nantes, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion